Iceland· IS-EU/1/21/1539/001
Abecma
A idecabtagene vicleucel product containing idecabtagenum vicleucelum inn, registered in Iceland by Bristol-Myers Squibb Pharma EEIG*. The same ATC class is registered in 10 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Idecabtagene vicleucel is registered in 10 of 19 countries.
Countries holding a registration under ATC L01XL07 (idecabtagene vicleucel), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 8 of them publish a price we can compare per daily dose
Idecabtagene vicleucel · ATC L01XL07
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Netherlands
- Polandprice
- Switzerlandprice
- United Statesprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Idecabtagenum Vicleucelum INN
- Manufacturer
- Bristol-Myers Squibb Pharma EEIG*
- Country
- Iceland (IS)
- ATC code
- L01XL07
- ATC class
- Idecabtagene vicleucel
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Idecabtagene vicleucel in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesAbecmaCelgene Corporation
- SwitzerlandAbecma Infusionsdispersion, von 260 bis 500 × 10e6 CAR-positiven lebensfähigen T-ZellenBristol-Myers Squibb SA
- CzechiaABECMABristol-Myers Squibb Pharma EEIG, Dublin
- SpainABECMA 260-500 x 10e6 CELULAS DISPERSION PARA PERFUSIONBristol-Myers Squibb Pharma Eeig
- FinlandAbecmaBristol-Myers Squibb Pharma EEIG
- BelgiumAbecma 260-500 x 10*6 cellsBristol-Myers Squibb Pharma
- IrelandAbecma 260 - 500 x 106 cells dispersion for infusionBristol-Myers Squibb Pharmaceuticals uc
- Japanイデカブタゲン ビクルユーセルブリストル・マイヤーズ スクイブ
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Abecma
- Norway · Abecma
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f718e0e7-68fa-4cbb-afba-bf97a9542500 GET /v1/drugs/f718e0e7-68fa-4cbb-afba-bf97a9542500?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Innrennslislyf, ördreifa",
"source": "lyfjastofnun",
"atc_raw": "L01XL07",
"marketed": false,
"strength": "260 - 500 × 10^6 frumur",
"ma_number": "EU/1/21/1539/001",
"substance": "Idecabtagenum Vicleucelum INN",
"other_info": "Markaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.",
"legal_status": "(R) Lyfseðilsskylt\r\n(H) Sjúkrahúsmerkt",
"ma_issued_serial": "44426"
}See everything about idecabtagene vicleucel.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.